Premium
Mini‐patient‐derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non‐small cell lung cancer
Author(s) -
Wang Xue,
Sun Yile,
Xu Yunhua,
Wen Danyi,
An Na,
Leng Xuejiao,
Fu Guolong,
Lu Shun,
Chen Zhiwei
Publication year - 2021
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.11622
Subject(s) - lung cancer , chemotherapy , medicine , oncology , mediastinum , surgery
Patient‐derived xenograft (PDX) assay has been widely used in preclinical research in patients with multidrug‐resistant lung cancer. One hundred patients with non‐small cell lung cancer (NSCLC) were divided into MiniPDX group and conventional group, with 50 cases in each group. The MiniPDX assay was established by enriching high‐purity tumor cells using microfluidic technology to detect the drug sensitivity of NSCLC cells. All patients underwent conventional computed tomography (CT) scans of lung and mediastinum at baseline and during follow‐up. Kaplan–Meier method was used to compare the overall survival and progression‐free survival of two groups. The sensitivity of the same drug in different tumor xenograft varied greatly. The overall survival, progression‐free survival, and clinical benefit rate of patients in the MiniPDX‐guided chemotherapy group were significantly longer than those in the conventional chemotherapy group. MiniPDX assay may be an effective tool for screening chemotherapy regimens in NSCLC patients.